- Hong Kong Pharma Digital Technology Holdings Limited announced significant **management changes** effective **October 6, 2025**, including the resignations of its CEO, Executive Director, and CFO, and the appointment of a new CEO, CFO, and Chief Strategy Officer.  **[2007702_0001213900-25-096731_ea0260472-6k_hongkong.htm:1]** 
- **Mr. Chenyu Liang** was appointed as Director and Chief Executive Officer, **Ms. Shu Liu** as Chief Financial Officer, and **Mr. Zifeng Wang** as Chief Strategy Officer.  **[2007702_0001213900-25-096731_ea0260472-6k_hongkong.htm:1]** 
- The new CEO, Mr. Liang, and CFO, Ms. Liu, will each receive an annual base salary of **HKD100,000**, while the new CSO, Mr. Wang, will receive **HKD70,000**.  **[2007702_0001213900-25-096731_ea0260472-6k_hongkong.htm:2]** 
- Their employment agreements have an initial term of **one year** and include severance provisions, such as a cash payment of **three months of base salary** upon termination without cause.  **[2007702_0001213900-25-096731_ea026047201ex99-1_hongkong.htm:0]** **[2007702_0001213900-25-096731_ea026047201ex99-2_hongkong.htm:0]** **[2007702_0001213900-25-096731_ea026047201ex99-1_hongkong.htm:2]** **[2007702_0001213900-25-096731_ea026047201ex99-2_hongkong.htm:2]** **[2007702_0001213900-25-096731_ea026047201ex99-3_hongkong.htm:2]**

Hong Kong Pharma Digital Technology Holdings (HKPD)